Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSF1R | P07333 | 4/20 | 1.00 |
| ▸ | KIT | P10721 | 3/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 5/20 | 0.56 |
| ▸ | LCK | P06239 | 1/20 | 0.56 |
| ▸ | PGR | P06401 | 1/20 | 0.56 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.56 |
| ▸ | HTR1A | P08908 | 1/20 | 0.56 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.56 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.56 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.56 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.56 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.56 |
| ▸ | FLT1 | P17948 | 1/20 | 0.56 |
| ▸ | DRD1 | P21728 | 1/20 | 0.56 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.56 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.56 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.56 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.56 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.56 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1268018 | 1.00 | CSF1R (1.00) | CSF1RKITCYP2C19LCKPGR | |
| Hydrochloric Acid SCHEMBL29973836 | 0.99 | CSF1R (0.98) | CSF1RKITCYP2C19LCKPGR | |
| Hydrochloric Acid SCHEMBL20166201 | 0.99 | CSF1R (0.98) | CSF1RKITCYP2C19LCKPGR | |
| SCHEMBL28770362 | 0.90 | CSF1R (0.81) | CSF1RKITCYP2C19LCKPGR | |
| SCHEMBL1268059 | 0.89 | CSF1R (0.80) | CSF1RKITCYP2C19LCKPGR | |
| SCHEMBL1267263 | 0.88 | CSF1R (0.79) | CSF1RKITCYP2C19LCKPGR | |
| SCHEMBL1267961 | 0.88 | CSF1R (0.79) | CSF1RKITCYP2C19LCKPGR | |
| SCHEMBL1267706 | 0.88 | CSF1R (0.79) | CSF1RKITCYP2C19LCKPGR | |
| SCHEMBL1266888 | 0.88 | CSF1R (0.79) | CSF1RKITCYP2C19LCKPGR | |
| SCHEMBL12646996 | 0.88 | CSF1R (0.78) | CSF1RKITCYP2C19LCKPGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 143 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260000652-A1 | IMPEDING PLATINUM-BASED CHEMOTHERAPEUTIC INDUCED OTOTOXICITY USING A COLONY STIMULATING FACTOR 1 RECEPTOR INHIBITOR | THE US SECRETARY DEPARTMENT OF HEALTH & HUMAN SERVICES (US) | 2026-01-01 | — | — | US | claimed |
| US-12421517-B2 | Genetic modification of mammalian cells to confer resistance to CSF1R antagonists | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-09-23 | — | — | US | claimed |
| EP-4551209-A1 | IMPEDING PLATINUM-BASED CHEMOTHERAPEUTIC INDUCED OTOTOXICITY USING A COLONY STIMULATING FACTOR 1 RECEPTOR INHIBITOR | The United States of America, as represented by the Secretary, Department of Health and Human Services (US) | 2025-05-14 | — | — | EP | claimed |
| US-20250002920-A1 | GENETIC MODIFICATION OF MAMMALIAN CELLS TO CONFER RESISTANCE TO CSF1R ANTAGONISTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2025-01-02 | — | — | US | claimed |
| US-20240325506-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF GAUCHER DISEASE | AVROBIO INC (US) | 2024-10-03 | — | — | US | claimed |
| WO-2024011253-A1 | IMPEDING PLATINUM-BASED CHEMOTHERAPEUTIC INDUCED OTOTOXICITY USING A COLONY STIMULATING FACTOR 1 RECEPTOR INHIBITOR | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2024-01-11 | — | — | WO | claimed |
| US-20230322897-A1 | COMPOSITIONS AND METHODS FOR TREATING NEUROCOGNITIVE DISORDERS | AVROBIO, INC. | 2023-10-12 | — | — | US | claimed |
| US-20230227847-A1 | VIRAL VECTORS EXPRESSING THERAPEUTIC PROTEINS SPECIFICALLY IN MYELOID CELLS AND MICROGLIA | UNIV ZUERICH (CH) | 2023-07-20 | — | — | US | claimed |
| US-20230165906-A1 | COMPOSITIONS AND METHODS FOR USING TRANSPLANTED MICROGLIA AS A VEHICLE FOR WIDESPREAD DELIVERY OF CELLS AND OTHER BIOLOGIC AGENTS TO THE BRAIN | ALBERT EINSTEIN COLLEGE OF MEDICINE | 2023-06-01 | — | — | US | claimed |
| EP-4175717-A2 | COMPOSITIONS AND METHODS FOR TREATING NEUROCOGNITIVE DISORDERS | Avrobio, Inc. (US) | 2023-05-10 | — | — | EP | claimed |
| EP-4158035-A1 | VIRAL VECTORS EXPRESSING THERAPEUTIC PROTEINS SPECIFICALLY IN MYELOID CELLS AND MICROGLIA | Universität Zürich (CH) | 2023-04-05 | — | — | EP | claimed |
| EP-4142745-A1 | COMPOSITIONS AND METHODS FOR USING TRANSPLANTED MICROGLIA AS A VEHICLE FOR WIDESPREAD DELIVERY OF CELLS AND OTHER BIOLOGIC AGENTS TO THE BRAIN | Albert Einstein College of Medicine (US) | 2023-03-08 | — | — | EP | claimed |
| CN-115552019-A | Viral vectors for the specific expression of therapeutic proteins in myeloid and microglia cells | 苏黎世大学 | 2022-12-30 | — | — | CN | claimed |
| WO-2022271944-A2 | COMPOSITIONS AND METHODS FOR TREATMENT OF GAUCHER DISEASE | AVROBIO, INC. (US) | 2022-12-29 | — | — | WO | claimed |
| US-20220412957-A1 | METHODS OF TREATING CANCER PATIENTS WITH RAS NODE OR RTK TARGETED THERAPEUTIC AGENTS | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2022-12-29 | — | — | US | claimed |
| EP-4073516-A1 | METHODS OF TREATING CANCER PATIENTS WITH RAS NODE OR RTK TARGETED THERAPEUTIC AGENTS | Celcuity Inc. (US) | 2022-10-19 | — | — | EP | claimed |
| WO-2022182982-A1 | METHODS FOR TREATING C-KIT KINASE MEDIATED DISEASES AND DISORDERS USING A SELECTIVE C-KIT KINASE INHIBITOR | THIRD HARMONIC BIO, INC. (US) | 2022-09-01 | — | — | WO | claimed |
| US-20220133808-A1 | COMPOSITIONS AND METHODS FOR TREATING NEUROCOGNITIVE DISORDERS | AVROBIO, INC. | 2022-05-05 | — | — | US | claimed |
| US-20220133850-A1 | COMPOSITIONS AND METHODS FOR TREATING NEUROCOGNITIVE DISORDERS | AVROBIO, INC. | 2022-05-05 | — | — | US | claimed |
| US-20220111005-A1 | COMPOSITIONS AND METHODS FOR TREATING NEUROCOGNITIVE DISORDERS | AVROBIO, INC. (US) | 2022-04-14 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260000652-A1 | IMPEDING PLATINUM-BASED CHEMOTHERAPEUTIC INDUCED OTOTOXICITY USING A COLONY STIMULATING FACTOR 1 RECEPTOR INHIBITOR | CSF1R, CSF3R, MCL1 | CSF1R 1/4885KIT 9/4885CYP2C19 2656/4885 |
| US-20230165906-A1 | COMPOSITIONS AND METHODS FOR USING TRANSPLANTED MICROGLIA AS A VEHICLE FOR WIDESPREAD DELIVERY OF CELLS AND OTHER BIOLOGIC AGENTS TO THE BRAIN | CSF1R, CSF3R, GMFG | CSF1R 1/4885KIT 244/4885CYP2C19 3470/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.